LNC
TOVX icon

Lincoln National Corp’s Theriva Biologics TOVX Stock Holding History

Lincoln National Corp’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-440
Closed -$5.16K – 1038
2024
Q1 		$5.16K Hold
440
– – ﹤0.01% 1202
2023
Q4 		$4.73K Buy
+440
New +$5.41K ﹤0.01% 1099
2018
Q1 		– Sell
-1
Closed -$6K – 608
2017
Q4 		$6K Buy
+1
New +$6.25K ﹤0.01% 635

Other funds holding TOVX

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Lincoln National Corp's TOVX Position: Q2 2024 in Review

Lincoln National Corp sold out of Theriva Biologics (TOVX) in Q2 2024, closing a stake of 440 shares — an estimated $5.16K sold.

Lincoln National Corp first reported a position in TOVX in Q4 2017 and held it in 3 quarters. The position peaked at $6K in Q4 2017. 20 funds tracked by Wall St. Rank hold TOVX as of Q2 2024.

  • Lincoln National Corp reported no remaining Theriva Biologics position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 440 Theriva Biologics shares in Q2 2024, an estimated $5.16K.
  • Lincoln National Corp first reported a position in Theriva Biologics in Q4 2017 and held it in 3 quarters.
  • Lincoln National Corp's Theriva Biologics position peaked at $6K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.